Institut Pasteur   Report issue

Foundation Phase 1 Phase 2 Phase 3 Phase 4
Founded: Paris France (1887)

Organization Overview

First Clinical Trial
2002
NCT00158496
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Centre Medical de l'Institut Pasteur | Director of the Institut Pasteur de Bangui, Central African Republic | Immunology Investigator, Pasteur Institut Paris | Institute Pasteur, Cambodia | Institute Pasteur Tunisia | Institut Pasteur | Institut Pasteur, Cambodia | Institut Pasteur Dakar | Institut Pasteur de Bangui | Institut Pasteur de Dakar | Institut Pasteur de Dakar, Senegal | Institut Pasteur de la Guyane | Institut Pasteur de Lille | Institut Pasteur de Lille - NutrInvest | Institut Pasteur de Madagascar | Institut Pasteur de Nouvelle-Calédonie | Institut Pasteur de Paris | Institut Pasteur de Tunis | Institut Pasteur du Cambodge | Institut Pasteur du Maroc | Institut Pasteur in Cambodia | Institut Pasteur in Madagascar (subject recruitment) | Institut Pasteur, Paris France | Institut Pasteur, Tunisia | Pasteur Institute, Ho Chi Minh City | Pasteur Institute of Ho Chi Minh City | Pasteur Institute of Iran, Tehran, Iran | Unité de Recherche et d'Expertise Epidémiologie des maladies émergentes, Institut Pasteur, Paris

Active Ingredients

Drugs in Phase 4 Trials (14)

artemisinin (1 trial)

bivalent oral polio vaccine (bopv), type 1 and type 3 (BOPV) (1 trial)

chloroquine (1 trial)

dihydroartemisinin (1 trial)

diphtheria, tetanus and whole cell pertussis vaccine (Boostrix) (1 trial)

DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine (Pediarix) (1 trial)

hepatitis b vaccine (recombinant) (Recombivax) (2 trials)

inactivated influenza vaccine (7 trials)

mebendazole (vermox) (1 trial)

piperaquine (2 trials)

polio, inactivated poliovirus vaccine (Salk Vaccine) (1 trial)

primaquine (2 trials)

quinvaxem (2 trials)

yellow fever vaccine 17d strain (1 trial)

Drugs in Phase 3 Trials (35)

albendazole (Albenza) (1 trial)

azithromycin (zithromax) (2 trials)

bacille calmette-guerin (4 trials)

bivalent bnt162b2 (Comirnaty) (1 trial)

centruroides (scorpion) immune f(ab')2 (equine) injection (Anascorp) (1 trial)

coronavac (1 trial)

darunavir (prezista) (1 trial)

emtricitabine (emtriva) (1 trial)

fluconazole (diflucan) (1 trial)

flucytosine (ancobon) (1 trial)

fructo-oligosaccharide (1 trial)

hydroxychloroquine (plaquenil) (2 trials)

interferon alpha-2b (Intron-A) (3 trials)

inulin (2 trials)

lamivudine (epivir) (1 trial)

live attenuated influenza virus vaccine (Flumist) (1 trial)

lopinavir (Kaletra) (1 trial)

maraviroc (selzentry) (1 trial)

mtbvac (1 trial)

multi-valent pneumococcal conjugate vaccine (1 trial)

paromomycin (humatin) (5 trials)

pneumococcal 13-valent conjugate vaccine (prevnar 13) (2 trials)

potassium alum (4 trials)

pyrimethamine (daraprim) (1 trial)

raltegravir (isentress) (1 trial)

ribavirin (virazole) (2 trials)

ritonavir (Norvir) (2 trials)

serogroup b meningococcal vaccine (Trumenba) (1 trial)

serogroup B meningococcal vaccine (Bexsero) (2 trials)

sulfadoxine (1 trial)

sulfamethoxazole (gantanol) (1 trial)

tenofovir (viread) (1 trial)

totum-63 (1 trial)

trimethoprim (1 trial)

vitamin d3 (1 trial)

Drugs in Phase 2 Trials (8)

montanide isa 720 (1 trial)

pflsa-3-rec (1 trial)

raav2/5-hnaglu (1 trial)

sc599 (1 trial)

sf2a-tt15 (1 trial)

theravac (1 trial)

vivomixx (1 trial)

vsl #3 (2 trials)

Drugs in Phase 1 Trials (6)

as15 (1 trial)

clade b hiv vaccine (1 trial)

gentamicin (garamycin) (1 trial)

mag-tn3 (1 trial)

sf2a-tt15 vaccine (1 trial)

tmv-083 (1 trial)

Drugs in Other Trials (13)

artesunate (2 trials)

elder flower (1 trial)

fish collagen peptides (1 trial)

fludeoxyglucose f-18 (1 trial)

glucose (1 trial)

inactivated rabies vaccine (Imovax) (2 trials)

maltodextrin (3 trials)

mefloquine (lariam) (1 trial)

oligofructose (2 trials)

serum (1 trial)

sucrose (2 trials)

whole blood (1 trial)

xylooligosaccharide (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 1)

Communicable Diseases (Phase 3)

Diabetes Mellitus, Type 2 (Phase 3)

Diphtheria (Phase 3)

Dysentery (Phase 1)

Dysentery, Bacillary (Phase 2)

Fever (Phase 4)

Glucose Intolerance (Phase 3)

Glucosephosphate Dehydrogenase Deficiency (Phase 4)

Haemophilus Infections (Phase 3)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis B (Phase 4)

Hepatitis B, Chronic (Phase 3)

Hepatitis C (Phase 3)

Hepatitis C, Chronic (Phase 3)

Hepatitis, Chronic (Phase 3)

HIV Infections (Phase 3)

Hypertriglyceridemia (Phase 3)

Infections (Phase 3)

Inflammatory Bowel Diseases (Phase 3)

Influenza, Human (Phase 4)

Influenza in Birds (Phase 1)

Insulin Resistance (Phase 3)

Intestinal Diseases (Phase 3)

Leishmaniasis (Phase 3)

Leishmaniasis, Cutaneous (Phase 3)

Malaria (Phase 4)

Malaria, Falciparum (Phase 4)

Malaria, Vivax (Phase 4)

Malnutrition (Phase 3)

Melanoma (Phase 2)

Meningitis (Phase 3)

Meningitis, Cryptococcal (Phase 3)

Mucopolysaccharidosis III (Phase 2)

Obesity (Phase 3)

Poisoning (Phase 3)

Prediabetic State (Phase 3)

Scorpion Stings (Phase 3)

Syndrome (Phase 2)

Tetanus (Phase 3)

Tetany (Phase 3)

Whooping Cough (Phase 4)

Yellow Fever (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 67
  • # of Trial APIs: 76